JP2006504751A - 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 - Google Patents
副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 Download PDFInfo
- Publication number
- JP2006504751A JP2006504751A JP2004544592A JP2004544592A JP2006504751A JP 2006504751 A JP2006504751 A JP 2006504751A JP 2004544592 A JP2004544592 A JP 2004544592A JP 2004544592 A JP2004544592 A JP 2004544592A JP 2006504751 A JP2006504751 A JP 2006504751A
- Authority
- JP
- Japan
- Prior art keywords
- parathyroid
- formula
- hydrogen
- methyl
- hyperparathyroidism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000002980 Hyperparathyroidism Diseases 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 150000003883 epothilone derivatives Chemical class 0.000 title claims description 20
- 238000000034 method Methods 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- -1 methoxy, ethoxy, amino, methyl amino, dimethylamino Chemical group 0.000 claims description 9
- 201000003913 parathyroid carcinoma Diseases 0.000 claims description 9
- 208000017954 parathyroid gland carcinoma Diseases 0.000 claims description 9
- 206010033964 Parathyroid tumour benign Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 8
- 201000003686 parathyroid adenoma Diseases 0.000 claims description 8
- 208000014643 parathyroid gland adenoma Diseases 0.000 claims description 8
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims description 8
- 230000002085 persistent effect Effects 0.000 claims description 8
- 230000000306 recurrent effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 5
- 230000000148 hypercalcaemia Effects 0.000 claims description 5
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 2
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 17
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 15
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 14
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229930013356 epothilone Natural products 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000006427 angiogenic response Effects 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000001142 anti-diarrhea Effects 0.000 description 3
- 229940125714 antidiarrheal agent Drugs 0.000 description 3
- 239000003793 antidiarrheal agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 0 C[C@](CCC[C@@](*)(*1)C1C[C@](*C(C[C@@](C(C)(C)C([C@@]1C)=O)O)=O)C(C)=Cc2c[s]c(*)n2)C1=O Chemical compound C[C@](CCC[C@@](*)(*1)C1C[C@](*C(C[C@@](C(C)(C)C([C@@]1C)=O)O)=O)C(C)=Cc2c[s]c(*)n2)C1=O 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229940050957 opium tincture Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000028198 tertiary hyperparathyroidism Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
AはOまたはNRNを表し、ここで、RNは水素または低級アルキルであり、Rは水素または低級アルキルであり、R'はメチル、メトキシ、エトキシ、アミノ、メチルアミノ、ジメチルアミノまたはメチルチオであり、そしてZはOまたは結合である。〕
のエポシロン誘導体または薬学的に許容されるその塩が、副甲状腺機能亢進症の処置に有益な効果を産生することが判明した。
血中の副甲状腺ホルモンレベルの低下、
尿中の副甲状腺ホルモンレベルの低下、
血中のカルシウムレベルの低下、
尿中のカルシウムレベルの低下、
骨密度の上昇。
Claims (16)
- 温血動物がヒトである、請求項2記載の方法。
- AがOを表し、Rがメチルであり、そしてZがOである式Iのエポシロン誘導体または薬学的に許容されるその塩を、必要とする温血動物に投与することを含む、請求項2記載の方法。
- 該エポシロン誘導体を、前回処置後1週間から6週間の間隔後に、約0.1から6mg/m2の用量を週に1回3週間投与することを含む、請求項4記載の方法。
- 副甲状腺機能亢進症がアデノーマ、過形成または癌腫である、請求項2から5のいずれかに記載の方法。
- 疾患が副甲状腺アデノーマ、副甲状腺過形成または副甲状腺癌腫である、請求項6記載の方法。
- 副甲状腺癌疾患が再発性もしくは持続性副甲状腺アデノーマ、再発性もしくは持続性副甲状腺過形成または再発性もしくは持続性副甲状腺癌腫である、請求項2から5のいずれかに記載の方法。
- 副甲状腺機能亢進症が原発性または二次性副甲状腺機能亢進症である、請求項2から5のいずれかに記載の方法。
- 温血動物がヒトである、請求項10記載の方法。
- AがOを表し、Rがメチルであり、そしてZがOである式Iのエポシロン誘導体または薬学的に許容されるその塩を、それを必要とする温血動物に投与することを含む、請求項10記載の方法。
- 該エポシロン誘導体を、前回処置後1週間から6週間の間隔後に、約0.1から6mg/m2の用量を週に1回3週間投与することを含む、請求項12記載の方法。
- 疾患が再発性もしくは持続性副甲状腺アデノーマ、再発性もしくは持続性副甲状腺過形成または再発性もしくは持続性副甲状腺癌腫である、請求項10から13のいずれかに記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41859202P | 2002-10-15 | 2002-10-15 | |
PCT/IB2003/004514 WO2004035050A1 (en) | 2002-10-15 | 2003-10-13 | Use of epothilone derivatives for the treatment of hyperparathyroidism |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006504751A true JP2006504751A (ja) | 2006-02-09 |
JP2006504751A5 JP2006504751A5 (ja) | 2006-11-30 |
JP4672368B2 JP4672368B2 (ja) | 2011-04-20 |
Family
ID=32107949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004544592A Expired - Fee Related JP4672368B2 (ja) | 2002-10-15 | 2003-10-13 | 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20060142354A1 (ja) |
EP (1) | EP1553938B1 (ja) |
JP (1) | JP4672368B2 (ja) |
CN (1) | CN1297269C (ja) |
AT (1) | ATE350034T1 (ja) |
AU (1) | AU2003267751A1 (ja) |
BR (1) | BR0315293A (ja) |
CA (1) | CA2501717C (ja) |
CY (1) | CY1106385T1 (ja) |
DE (1) | DE60310975T2 (ja) |
DK (1) | DK1553938T3 (ja) |
ES (1) | ES2279139T3 (ja) |
HK (1) | HK1080768A1 (ja) |
PT (1) | PT1553938E (ja) |
SI (1) | SI1553938T1 (ja) |
WO (1) | WO2004035050A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
ATE350383T1 (de) | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001504474A (ja) * | 1996-11-18 | 2001-04-03 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | エポチロンc,d,e及びf、製造と薬剤 |
JP2002502810A (ja) * | 1998-02-05 | 2002-01-29 | ノバルティス アクチエンゲゼルシャフト | エポシロン組成物 |
US20020119202A1 (en) * | 1993-07-19 | 2002-08-29 | Hunter William L. | Anti-angiogenic compositions and methods of use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
-
2003
- 2003-10-13 CA CA2501717A patent/CA2501717C/en not_active Expired - Fee Related
- 2003-10-13 AU AU2003267751A patent/AU2003267751A1/en not_active Abandoned
- 2003-10-13 US US10/530,855 patent/US20060142354A1/en not_active Abandoned
- 2003-10-13 WO PCT/IB2003/004514 patent/WO2004035050A1/en active IP Right Grant
- 2003-10-13 EP EP03748446A patent/EP1553938B1/en not_active Expired - Lifetime
- 2003-10-13 BR BR0315293-6A patent/BR0315293A/pt not_active IP Right Cessation
- 2003-10-13 SI SI200330741T patent/SI1553938T1/sl unknown
- 2003-10-13 DK DK03748446T patent/DK1553938T3/da active
- 2003-10-13 PT PT03748446T patent/PT1553938E/pt unknown
- 2003-10-13 CN CNB200380101281XA patent/CN1297269C/zh not_active Expired - Fee Related
- 2003-10-13 DE DE60310975T patent/DE60310975T2/de not_active Expired - Lifetime
- 2003-10-13 ES ES03748446T patent/ES2279139T3/es not_active Expired - Lifetime
- 2003-10-13 AT AT03748446T patent/ATE350034T1/de active
- 2003-10-13 JP JP2004544592A patent/JP4672368B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-13 HK HK06100631A patent/HK1080768A1/xx not_active IP Right Cessation
-
2007
- 2007-03-15 CY CY20071100363T patent/CY1106385T1/el unknown
-
2011
- 2011-03-01 US US13/037,989 patent/US20110152329A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119202A1 (en) * | 1993-07-19 | 2002-08-29 | Hunter William L. | Anti-angiogenic compositions and methods of use |
JP2001504474A (ja) * | 1996-11-18 | 2001-04-03 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | エポチロンc,d,e及びf、製造と薬剤 |
JP2002502810A (ja) * | 1998-02-05 | 2002-01-29 | ノバルティス アクチエンゲゼルシャフト | エポシロン組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1297269C (zh) | 2007-01-31 |
HK1080768A1 (en) | 2006-05-04 |
DE60310975D1 (de) | 2007-02-15 |
US20110152329A1 (en) | 2011-06-23 |
CY1106385T1 (el) | 2011-10-12 |
CA2501717A1 (en) | 2004-04-29 |
PT1553938E (pt) | 2007-03-30 |
DK1553938T3 (da) | 2007-03-26 |
EP1553938A1 (en) | 2005-07-20 |
WO2004035050A1 (en) | 2004-04-29 |
CA2501717C (en) | 2012-09-18 |
SI1553938T1 (sl) | 2007-06-30 |
AU2003267751A1 (en) | 2004-05-04 |
CN1703217A (zh) | 2005-11-30 |
DE60310975T2 (de) | 2007-07-12 |
JP4672368B2 (ja) | 2011-04-20 |
BR0315293A (pt) | 2005-08-30 |
ES2279139T3 (es) | 2007-08-16 |
EP1553938B1 (en) | 2007-01-03 |
US20060142354A1 (en) | 2006-06-29 |
ATE350034T1 (de) | 2007-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006176542A (ja) | フェニルエテンスルホンアミド誘導体含有医薬 | |
US20090227608A1 (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia | |
JP2019011343A (ja) | 選択的s1p1レセプターアゴニストを含む薬学的合剤 | |
US20040146498A1 (en) | Pharmaceutical combinations | |
US20110033458A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
US20090246172A1 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
JP2016179994A (ja) | イネカルシトールの新しい治療的使用 | |
KR20040106422A (ko) | 간암 및 다른 암 질병 치료용 에포틸론 유도체 | |
JP2020520374A (ja) | 関節リウマチの治療用組成物および治療方法 | |
JP4672368B2 (ja) | 副甲状腺機能亢進症の処置のためのエポシロン誘導体の使用 | |
KR930007252B1 (ko) | 우울증 치료용 약학조성물 | |
KR20160003652A (ko) | 감마―글루타밀 주기 조절 방법 및 조성물 | |
JPWO2004096230A1 (ja) | 関節リウマチ治療剤 | |
AU2003223958B2 (en) | Combinations comprising epothilone derivatives and alkylating agents | |
US20060094766A1 (en) | Epothilone derivatives for the treatment of multiple myeloma | |
AU2002366531B2 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
WO2021119108A1 (en) | Use of fgfr inhibitors for treatment of idiopathic short stature | |
JP2004250441A (ja) | 血小板大凝集塊の形成阻害剤 | |
JPH06183978A (ja) | 血小板凝集抑制組成物 | |
AU2007200588A1 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
ZA200404013B (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061012 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061012 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20091224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100506 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100519 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101110 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110111 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110119 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |